ASRM 2024 Abstract Submission is Open!

Close Close Icon

Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion (2019)


  • For the purposes of this statement, ‘‘futility’’ refers to treatment that has a <1% chance of achieving a live birth; ‘‘very poor prognosis’’ refers to treatment for which the odds of achieving a live birth are very low but not nonexistent (1% to<5% per cycle).
  • Clinicians may refuse to initiate a treatment option they regard as futile or having a very poor prognosis. Referral information should be offered, if appropriate.
  • Decisions about treating or refusing to treat couples or individuals always should be patient-centered. Protection of a fertility center's success rates is not an ethical basis for refusing to treat those with futile or very poor prognoses. Conversely, care should not be provided to benefit the provider or center financially.
  • Upon request, clinicians may treat patients in cases of futility or very poor prognosis on a limited basis to fulfill patients' psychological needs, but only if the clinician has assessed the risks and benefits and has implemented a process, detailed in this opinion, for fully informing the patients of the low chance of success, eliciting their values, and ensuring their comprehension.
  • Thorough discussions are advisable at the beginning of the patient-physician interaction when patients have indicators of futile or very poor prognosis.
  • Fertility centers should develop policies to guide evidence-based decisions about treating those with futile or very poor prognoses. They should provide their patients with clinic-specific success rates and should inform them if they are aware of other centers with better outcomes, where their prognoses may be improved.
  • Clinicians should make decisions to refuse to initiate or continue infertility treatment in cooperation with the patients. Toward this end, it is advisable for clinicians periodically to revisit the treatment plan in a process of shared decision-making with patients.


Many patients who seek fertility services have a reasonable chance of succeeding in their goal of having a child. Others, however, have a very low or, in some cases, nearly nonexistent chance of achieving that goal. While most patients set their own limits to treatment, others, when told of remote prospects of success, have difficulty changing treatment protocols or ending their efforts to reproduce. Such situations may produce conflicts between clinicians and their patients. On the one hand, patients have interests in trying to do all they can to have a child and in making autonomous decisions about medical treatment. On the other hand, the clinician's duty as a medical professional is to provide care that offers benefits to patients, which is not served by offering treatments that are virtually certain to fail. Misunderstandings, disagreements, or conflicts may arise when patients seek to initiate or continue treatment regarded by practitioners as having either a very low or virtually nonexistent chance of success.

How should disagreements between patients and practitioners over the utility of treatment be managed? This document first reviews the applicable ethical precepts. Next, it addresses the conditions under which clinicians may refuse treatment based on predictions of remote success. Third, it discusses ways of minimizing confusion, of imparting bad news, and of preventing conflicts between clinicians and patients over the usefulness of requested treatments.


For Patients

Reproductive autonomy. Reproductive autonomy is a core value in reproductive medical ethics. It represents a right to be protected from interference with one's access to treatment by the state or others. It also can be understood as an ethical claim to have reproductive services provided. This aspect of reproductive autonomy is limited, however, as will be discussed herein. When a patient seeks treatment that is judged by the physician, based on evidence, to be futile or to carry a very poor prognosis, the patient does not have an absolute right to insist upon that treatment (1–3).

The American Medical Association (AMA) has described the balance of these values in this way: ‘‘Requests for interventions that are not medically appropriate challenge the physician to balance obligations to respect patient autonomy and not to abandon the patient with obligations to be compassionate, yet candid, and to preserve the integrity of medical judgment’’ (4).

For the Physician

Beneficence and professional integrity. The question of handling conflicts between physicians and patients over whether to initiate or continue with a treatment option raises basic ethical issues about rights and duties in the physician-patient relationship. This relationship is typically consensual, with couples or individuals and physicians free to enter or not enter into a relationship as they choose. The ability to decline to provide medical treatment relates directly to fertility treatments that have a very low or nonexistent chance of success, particularly when the physician believes the requested treatment may harm the patient (5–7).

The ethical principle of beneficence creates the professional responsibility to act for the patient's welfare. Thus, after accepting a patient, clinicians must use their best efforts on the patient's behalf, provide the applicable standard of medical services, engage in a process of informed consent, and respect the patient's autonomy. These duties do not, however, obligate physicians to provide services when, in their good faith medical judgment, the treatment is unlikely to achieve the patient's treatment goals. If a clinical intervention is reliably predicted to produce no such benefit, there is no ethical obligation to provide it (Brett 1986; Brett 2007). Professional integrity creates an ethical obligation to pursue excellence in patient care and also serves the values of the medical profession as a whole (1, 2).


The chances that fertility treatment will successfully lead to a live birth vary with the patient, treatment, and other conditions. Some treatments have such a low chance of success that they may be considered futile, while others, though not futile, may have a very poor prognosis. Because classifying a treatment as ‘‘futile’’ or ‘‘very poor prognosis’’ has different implications, we discuss each separately.


The term ‘‘futility’’ usually is used in situations in which a given treatment has virtually no chance of achieving the desired medical end. The concept is most commonly used in relation to end-of-life decisions. In that context, the AMA and others have elaborated on the complex meanings of futility and on the challenges of defining it (1, 4, 8). Many recognize both quantitative and qualitative aspects of the concept: on the quantitative side, there is likelihood that a treatment will achieve physiologic goals; on the qualitative side, the value of the treatment may contribute to the patient's quality of life (9). The AMA has identified as futile ‘‘interventions that, in [the physician's] best medical judgment, cannot reasonably be expected to yield the intended clinical benefit or achieve agreed-on goals for care’’ (4).

We believe this definition for futile care can be applied to the treatment of infertility. Treatment is futile in the quantitative sense when the desired physiologic goal is a live birth but there is no or virtually no reasonable likelihood that this goal will be achieved through the proposed treatment. Treatment can also be judged as futile in the qualitative sense when it will not serve to fulfill a goal important to the patient's quality of life.

Assessing Clinical Futility

The Ethics Committee views treatment (for example, an in vitro fertilization [IVF] or insemination cycle) as ‘‘futile’’ if it has a <1% chance of achieving a live birth. This calculation relies on various criteria that clinicians take into account when considering a likely outcome, such as the non-availability of adequate spermatozoa, the age of the female partner, or the patient's previous poor response. Clinicians should be circumspect about using ovarian reserve testing to assess futility in light of its limited predictive capacity, as detailed in this Society's recent review of the research literature (10). Futility also may be judged from a fertility center's own data, such as if the center has never achieved a pregnancy during application of the treatment to a patient with a particular profile, or, with caution, from national or international data. With this and all assessments of patients' chances, clinicians should be wary of erroneously estimating that a given individual's chances are the same as the average of the group to which he or she belongs (11).

Examples of treatment plans likely to be futile are those in which couples try IVF treatments with their own gametes when the female partner has ovarian failure, the male partner lacks viable spermatozoa, or the couple has undergone several IVF cycles without adequate egg production, fertilization, or embryo development. The determination of futility may change if patients modify their treatment plan, for example, by trying gamete or embryo donation after unsuccessful attempts with their own gametes.

Recognizing Psychological Goals

Situations may arise where the clinician fairly determines that treatment has little or no chance of resulting in pregnancy and live birth, but the patient nonetheless requests it in order only to receive a psychological benefit or to fulfill a religious belief. Benefits such as resolving questions about their fertility, being able to have hope, obtaining closure, acting in accord with their faith, and knowing they tried assiduously can be valid goals for limited treatment. Thus, an unsuccessful outcome, while disappointing, may still bring benefit from the patient's perspective, although the amount of benefit should be weighed carefully against the physical risks and costs of treatment (12).

Several things complicate defining and assessing futility. Patients and clinicians may interpret prognoses differently. Patients who hear that the odds of a live birth for their particular profile are 1% may perceive this as hopeful, and therefore not futile, when members of the medical team conclude that these odds are too low to proceed. At the same time, assessing the odds of success often is not a straightforward matter. Any clinician who has been surprised by an unexpected pregnancy knows to be humble about the limits of our capacity to predict outcomes perfectly. In addition to nature's capriciousness, a growing literature indicates that clinicians are not immune to cognitive biases and shortcuts that may cause them to overestimate or underestimate a treatment's utility (13).

The values clinicians hold as medical professionals may also affect their assessments in such situations. They may consider it wasteful or even fraudulent to participate in a treatment they believe in advance will not work. With large professional teams necessary to carry out some treatments, the entire staff may experience frustration and a sense of failure when they provide services that have a very remote chance of success. On the other hand, clinicians may empathize with their patients' overriding desire to attempt pregnancy and may wish to avoid delivering (and enforcing) bad news.

The Ethics Committee finds that it is an appropriate exercise of professional integrity for clinicians to refuse to offer, initiate, or continue treatment when, in their informed professional judgment, they regard such treatments as having a <1% chance of success and, thus, as being futile. In refusing to offer such treatment, physicians may consider not only the extremely remote chance of success but also the physical and psychological risk posed by the treatment. Physical risks may arise in fertility treatments for both men and women, but the risks generally are of greater concern for the woman undergoing IVF. If the risks are heightened, such as when a woman would need complex reconstructive surgery prior to assisted reproduction or when a man with nonobstructive azoospermia has already experienced several failed sperm retrieval procedures, there is further basis for refusing to provide futile treatment.

Psychological risks arise when, among other things, repeated efforts are unproductive and prevent patients from reassessing their reproductive options. Physicians may believe these risks are justified when the prognosis is very poor but not when the odds of success are virtually zero. In reaching a decision not to proceed, clinicians should follow guidelines and policies of the fertility practice that avoid arbitrary decisions. They should clearly explain their reasoning to the patients, including why they regard the proposed treatment to be futile, and should discuss gamete donation, adoption, and other alternatives. The discussion may include referral to another practice, either for a second opinion or because the patient's prognosis at another practice might be improved.

However, the Ethics Committee also finds that clinicians may ethically offer treatments they deem to be physiologically futile in circumstances where the risks are minimal, and the understood goal of the patient is to receive a psychological benefit from proceeding (14). In such a case, the patient's general welfare may be enhanced by a limited attempt at treatment, a goal still compatible with the duty of beneficence understood in its psychosocial dimension.

Before undertaking such treatment, however, the Committee recommends that a stepwise process be implemented. First, the clinician should explain the evidence base for his or her clinical judgment that the requested assisted reproduction is futile. In doing so, the physician should be attentive to indications that the patient possesses false or incomplete information, in which case s/he should respond by respectfully providing the information the patient needs to make an informed and reflective assessment of the clinician's recommendation. The clinician also should be attentive to external influences, such as pressure from a partner, spouse, or other family member. If such influences unjustifiably interfere with the patient's reproductive autonomy, the clinician should seek to minimize their role. The clinician should ask the patient what is important to him or her regarding reproductive treatment, to elicit the patient's values, and should repeat the recommendation against assisted reproduction with their own gametes and/or uterus. If the patient reaches an informed judgment that, despite the high predicted failure rate and risk of physical and psychological harms, the fertility treatment supports his/her values and/or psychological needs, it is compatible with professional integrity and reproductive liberty either to provide assisted reproduction on a limited basis or to refuse to provide assisted reproduction.

Psychological consultation is highly recommended for couples and individuals prior to undertaking treatment in such situations. For patients whose motivations are religious, suggesting that they seek religious advice about forgoing assisted reproductive technology may be valued. Informed consent conversations should be appropriately documented, including success rates, risks, outcomes, and alternative treatments. Financial benefit to the physician or center is not an acceptable ground for providing a treatment the physician believes is futile.

Very Poor Prognosis

In cases of very poor prognosis, the odds that a treatment (for example, an IVF or insemination cycle) will achieve a live birth are very low but not nonexistent (1% to <5% per cycle) and are thus not described here as futile. For example, a 44-year-old woman with a normal follicle-stimulating hormone level may have a very low but not nonexistent prospect for success with IVF at some fertility centers.

Decision-making in cases of very poor prognosis may be more complex than in cases of futility. Patients have a greater justification for insisting on their desired treatment option when the odds of success are somewhat higher. Also, when the outcome is more difficult to predict, some patients may view their chance of success as greater than that estimated by the physician. Indeed, as research proceeds and experience evolves, situations that once appeared to yield very poor prognoses may now produce improved outcomes in some centers, as has occurred with treatments for nonobstructive azoospermia (15).

As with futile prognoses, the values and goals of patients and clinicians in cases of very poor prognosis may differ. The patients may have an emotional need to feel that all reasonable medical avenues for having a child have been tried. Clinicians may be concerned about providing care with very low likelihood of success and must factor in the physical risks that are posed. In addition, current requirements to report outcome data may reward centers that accept only couples or individuals with good prognoses and thus create a motivation for refusing to treat those with very poor prognoses. Protecting success rates, however, is not an ethical basis for refusing to treat those with poor prognoses; neither is providing treatment for the financial benefit of the provider(s). In cases of very poor prognosis, the Ethics Committee finds that clinicians who determine that the chances of physiologic or psychological benefit are sufficient to make risks acceptable may justifiably proceed with the patient's preferred treatment on a limited basis; the patient must be fully informed of the prognosis, risks, and costs of treatment. It is recommended that clinicians initiate a stepwise communication process with patients, as was described in the case of futility, to elicit the bases for their treatment wishes and their values.

However, clinicians may ethically refuse to accept or to provide further treatment to couples and individuals with very poor prognoses provided that they make an evidence-based determination and follow guidelines and policies of the fertility practice that avoid arbitrary decisions. In either case, sufficient information must be conveyed to the couple or individual for them to understand what is being recommended and why. This information should be tailored and individualized as much as possible to the circumstances of the individual or couple. The interchange should include referral to psychological counseling. In deciding whether to proceed, the treatment team should, together with the couples or individuals, carefully consider the value systems and other factors that affect the couple's or individual's insistence on further treatment.


Fertility practices can take several steps to prevent disagreements or conflicts over initiating or continuing fertility treatments. One important step is to develop explicit policies to guide decisions about initiating or stopping treatment due to futile or very poor prognosis. An example would be the ‘‘conscientious practice policy,’’ developed in response to a recommendation of the AMA (16). Although not all situations can be anticipated, policies can encourage clinicians and patients to think prospectively about poor outcomes. Policies should inform couples and individuals of the medical criteria used to accept patients, the program's limits concerning treatment, and the circumstances in which the program may refuse to provide additional services. For example, a policy may state that IVF treatment will be refused or stopped when it has never succeeded at the clinic for a particular patient profile. Or, a policy may state that physicians will confer as a team to make futility determinations; for some patients, bad news will be easier to accept if it is the consensus of several physicians. It is advisable to retain some flexibility in developing the policies, however, and policies should not be so strict as to fail to take into account the circumstances or emotional needs of patients or the differences of opinion among clinicians within a practice. The policies should stress communication and agreement (4, 17).

A second important step is for clinicians to discuss these policies with potential patients when initial treatment decisions are made and as treatment proceeds (18). These discussions should include information about the chances of success and the circumstances in which treatment may not be offered or continued. Such discussion is especially important if patients present with a profile associated with a low likelihood of success, but it is not limited to these groups since the balance of benefits and probabilities facing any patient may shift over time. Patients should be apprised of endpoints and results in the treatment plan that signal when the team will reconsider continuing the treatment (19). During the consent process, physicians should be forthright and thorough in explaining the proposed treatment plan. Information about success rates should be conveyed to all couples and individuals, and it should include rates at the program as well as national averages. It is also appropriate to disclose if, to the clinician's knowledge, other programs have reported greater success in treating the patient's conditions and, if so, to offer referral if the patients desire. Referral to psychological counselors and other professionals should be discussed. Clinicians should recognize that their refusal to continue when faced with very poor or futile prognoses may help patients by encouraging them to consider alternative ways of achieving parenthood or to accept not having children.

After patients begin treatment, it is also important for them periodically to reevaluate their situation and goals. Members of the medical team should be involved in discussions about currently available treatments, steps that will be taken if certain events occur or fail to occur, and decisions regarding when it will be time to stop and examine other options. The discussion may need to be very specific. At the same time, the treatment team must consider the needs of the patients, realizing that the drive to continue may be enhanced by specific circumstances or psychological needs.

A third approach that may help minimize conflicts is for clinicians to learn to become more comfortable imparting the bad news of futile or very poor prognosis. Since Dr. John Gregory (1724-1773) wrote the first professional medical ethics, it has been recognized that to a physician ‘‘of compassionate and feeling heart, this is one of the most disagreeable duties in the profession: but it is indispensable.’’ We encourage clinicians to pursue education and training in the art of imparting bad news. The medical literature provides a range of recommended approaches, all of them generally incorporating advice to establish a setting free from interruption; to elicit the patient's understanding of his or her medical situation; to gently share information about the prognosis, ensure it is understood, and compassionately deal with reactions, including validating the patient's emotions (20).


Most patients recognize when they have reached a point where further treatment is not going to result in a successful pregnancy, and they will either stop their efforts or look for other means of achieving parenthood. Some, however, find it difficult to stop pursuing their hoped-for goal and they insist on further treatment. The Ethics Committee recommends development of patient-centered policies for each IVF center to enable clinicians to make evidence-based assessments. In most cases, the provision of futile therapies is not ethically justifiable, but when a patient seeks to receive only a psychological benefit, limited treatment may be provided after a process of explicit education and examination of values. For those treatments with very poor success rates, clinicians must be vigilant in their presentation of risks, benefits, and alternatives.

Acknowledgments: This report was developed by the Ethics Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. While this document reflects the views of members of that Committee, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment in all cases. This report was approved by the Ethics Committee of the American Society for Reproductive Medicine and the Board of Directors of the American Society for Reproductive Medicine.

The following members of the ASRM Ethics Committee participated in the review of this document. All Committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document. Judith Daar, J.D.; Jean Benward, M.S.W.; Lee Collins, J.D.; Joseph Davis, D.O.; Owen Davis, M.D.; Leslie Francis, Ph.D., J.D.; Elena Gates, M.D.; Elizabeth Ginsburg, M.D.; Susan Gitlin, Ph.D.; William Hurd, M.D., M.P.H.; Sigal Klipstein, M.D.; Laurence McCullough, Ph.D.; Richard Reindollar, M.D.; Ginny Ryan, M.D.; Mark Sauer, M.D., M.S.; Sean Tipton, M.A.; Lynn Westphal, M.D.; Julianne Zweifel, Ph.D.


  1. Tomlinson T, Brody H. Futility and the ethics of resuscitation. JAMA 1990; 264:1276–80.
  2. Brett AS, McCullough LB. Addressing requests by patients for nonbeneficial interventions. JAMA 2007;307:149–50.
  3. Brett A, McCullough LB. When patients request specific interventions: defining the limits of the physician's obligations. N Engl J Med 1986;315: 1347–51.
  4. American Medical Association. Code of medical ethics. Chapter 5.5: Medically ineffective interventions (2016). Available at: Accessed January 23, 2019.
  5. The New York State Task Force on Life and the Law. Assisted reproductive technologies: analysis and recommendations for public policy. Albany, NY: Health Education Services; 1998. Available at: Accessed January 23, 2019.
  6. Jecker NS, Schneiderman LJ. Medical futility: the duty not to treat. Camb Q Healthc Ethics 1993;2:151–9.
  7. Greiner GG. The physician's authority to withhold futile treatment. J Med Philos 1995;20:207–24.
  8. Lantos JD, Singer PA, Walker RM, Gramelspacher GP, Shapiro GR, Sanchez-Gonzalez MA, et al. The illusion of futility in clinical practice. Am J Med 1989; 87:81–4.
  9. Schneiderman LJ, Jecker NS, Jonsen AR. Medical futility: its meaning and ethical implications. Ann Intern Med 1990;112:949–54.
  10. ASRM Practice Committee. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2015;103:e9–17.
  11. Gould SJ. The Median Isn't the Message. Discover 1985;6:40–2. Available at: Accessed January 23, 2019.
  12. Aghabarary M, Nayeri ND. Medical futility and its challenges: a review study. J Med Ethics Hist Med 2016;9:11–23.
  13. Saposnik G, Redelmeier D, Ruff C, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Making 2016;16:138. Accessed January 23, 2019.
  14. Clapp D. Helping patients know when ‘enough is enough’. Sex Reprod Menopause 2004;2:159–62.
  15. Hopps CV, Goldtein M, Cshlegel PN. The diagnosis and treatment of the azoospermic patient in the age of intracytoplasmic sperm injection. Urol Clin North Am 2002;29:895–911.
  16. Mercurio MR. The conscientious practice policy: a futility policy for acute care hospitals. Conn Med 2005;69:417–9.
  17. Daar JF. Medical futility and implications for patient autonomy. Am J L Med 1995;XXI:221–40.
  18. The American College of Obstetricians and Gynecologists. Committee opinion: informed consent. No. 439, August 2009. Available at: https:// Committee-on-Ethics/Informed-Consent. Accessed January 23, 2019.
  19. English DC. Valid informed consent: a process, not a signature. Am Surg 2002;68:45–8.
  20. Monden KR, Gentry L, Cox TR. Delivering bad news to patients. Proc (Bayl Univ Med Cent) 2016;29:101–2.

Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.
Ethics Committee teaser

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility.
Ethics Committee teaser

Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion (2024)

Clinicians should encourage disclosure between intimate partners but should maintain confidentiality where there is no harm to the partner and/or offspring.
Ethics Committee teaser

Ethical considerations for telemedical delivery of fertility care: an Ethics Committee opinion (2024)

Telemedicine has the potential to increase access to and decrease the cost of care.
Ethics Committee teaser

Misconduct in third-party assisted reproductive technology by participants and nonmedical professionals or entities: an Ethics Committee opinion (2023)

In some instances, it is ethically permissible for the physician to either disclose material information to the affected party or to decline to provide or continue to provide care.

More Resources

MAC 2021 teaser
ASRM Academy on the Go

ASRM MAC Tool 2021

The ASRM Müllerian Anomaly Classification 2021 (MAC2021) includes cervical and vaginal anomalies and standardize terminology within an interactive tool format.

View the MAC Tool
EMR Phrases teaser
Practice Guidance

EMR Shared Phrases/Template Library

This resource includes phrases shared by ASRM physician members to provide a template for individuals to create their own EMR phrases.

View the library
Practice Committee Documents teaser

ASRM Practice Documents

These guidelines have been developed by the ASRM Practice Committee to assist physicians with clinical decisions regarding the care of their patients.

View ASRM Practice Documents
Ethics Committee teaser

ASRM Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.

View ASRM Ethics Opinions
Coding Corner general teaser
Practice Guidance

Coding Corner Q & A

The Coding Corner Q & A is a list of previously submitted and answered questions from ASRM members about coding. Answers are available to ASRM Members only.

View the Q & A
Covid-19 teaser
Practice Guidance

COVID-19 Resources

A compendium of ASRM resources concerning the Novel Corona virus (SARS-COV-2) and COVID-19.

View the resources
Couple looking at laptop for online patient education materials

Patient Resources provides a wide range of information related to reproductive health and infertility through patient education fact sheets, infographics, videos, and other resources.

View Website

Topic Resources

View more on legal/ethical issues
Webinars Icon

Apr 30, 2024, 3:00PM CT - "What is an Embryo’? Historical, psychological, and legal answers and implications

While an embryo is defined as “a fertilized egg that has begun cell division”, the meaning ascribed to embryos is far more complex.

Register Now
Document Icon

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility. View the Committee Opinion
Document Icon

Ethical considerations for telemedical delivery of fertility care: an Ethics Committee opinion (2024)

Telemedicine has the potential to increase access to and decrease the cost of care. View the Committee Opinion
Podcast Icon

ASRM Today: Policy Matters: Policy Roundup

On this episode of Policy Matters the ASRM Government Affairs Office brings us up to date on the past year of policy news and advocacy. Listen to the Episode
Document Icon

Interests, obligations, and rights in gamete and embryo donation: an Ethics Committee opinion (2019)

This Ethics Committee report outlines the interests, obligations, and rights of all parties involved in gamete and embryo donation: both males and females who choose to provide gametes or embryos for use by others, recipients of donated gametes and embryos, individuals born as a result of gamete or embryo donation, and the programs that provide donated gametes and embryos to patients. View the Committee Opinion
Legal Icon

The Supreme Court Overturns Right to Abortion, Raising Questions and Uncertainties for ART Patients and Providers

A summary of the U.S. Supreme Court’s ruling and various opinions in Dobbs v. Jackson Mississippi Women’s Health. View the Column
Document Icon

Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion (2022)

Providers may conclude that the medical risks of fertility treatment for a given patient are too high, in which case it is ethical for them to decline to provide treatment. View the Committee Opinion
Document Icon

Access to fertility services by transgender and nonbinary persons: an Ethics Committee opinion (2021)

The provision of fertility services to transgender individuals and the denial of access to fertility services is not justified. View the Committee Opinion
Document Icon

Interpretation of clinical trial results: a committee opinion (2020)

Evidence from clinical trials is fundamental to ethical medical practice. View the Committee Opinion
Document Icon

Ethics in embryo research: a position statement by the ASRM Ethics in Embryo Research Task Force and the ASRM Ethics Committee (2020)

Scientific research using human embryos advances human health and offspring well-being and provides vital insights into the mechanisms for reproduction and disease. Research involving human embryos is ethically acceptable if it is likely to provide significant new knowledge that may benefit human health, well-being of the offspring, or reproduction. View the Committee Opinion
Document Icon

Compassionate transfer: patient requests for embryo transfer for nonreproductive purposes (2020)

A patient request to transfer embryos into her body in a location or at a time when pregnancy is highly unlikely ... View the Committee Opinion
Document Icon

Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an Ethics Committee opinion (2018)

Preimplantation genetic testing for monogenic diseases for adult-onset conditions is ethically permissible for a range of conditions including when the condition is serious and no safe, effective interventions are available. View the Committee Document
Document Icon

Child-rearing ability and the provision of fertility services: an Ethics Committee opinion (2017)

Fertility programs may withhold services from prospective patients on the basis of well-grounded reasons that those patients will be unable to provide minimally adequate or safe care for offspring. View the Committee Opinion
Document Icon

Using family members as gamete donors or gestational carriers (2017)

The use of adult intrafamilial gamete donors and gestational surrogates is generally ethically acceptable when all participants are fully informed. View the Committee Document
Document Icon

Financial ‘‘risk-sharing’’ or refund programs in assisted reproduction: an Ethics Committee opinion (2016)

Financial ‘‘risk-sharing’’ fee structures in assisted reproduction programs charge patients a higher initial fee but provide reduced fees for subsequent cycles and often a partial or complete refund if treatment fails. View the Committee Document
Document Icon

Disclosure of medical errors involving gametes and embryos: an Ethics Committee opinion (2016)

Medical providers have an ethical duty to disclose clinically significant errors involving gametes and embryos as soon as they are discovered. Clinics also should have written policies in place for reducing and disclosing errors. View the Committee Document
Document Icon

Informed consent and the use of gametes and embryos for research: a committee opinion (2014)

The ethical conduct of human gamete and embryo research depends upon conscientious application of principles of informed consent. View the Committee Opinion

Topic Resources

View more on the topic of infertility
Document Icon

Tobacco or marijuana use and infertility: a committee opinion (2023)

In the United States, approximately 21% of adults report some form of tobacco use, although 18% report marijuana use. View Committee Opinion
Advocacy Icon

National Infertility Awareness Week

April 21-27, 2024, is National Infertility Awareness Week (NIAW)! This year’s theme is “Leave Your Mark.”

View the NIAW Toolkit
Videos Icon

Journal Club Global: The future of REI Fellowship training: debating opportunities and threats

This exciting collaboration discusses the controversy and future directions for the field of Reproductive Endocrinology and Infertility medicine. View the Video
Videos Icon

Journal Club Global: Infertility and Subclinical Hypothyroidism

The impact of treating SCH on fertility, obstetric outcomes, and offspring neurocognitive development is debated in the literature. View the Video
Announcement Icon

ASRM reacts to Alabama legislation

We are pleased that the legislation passed into law by the Alabama General Assembly will at least allow our members in the state to care for their patients.

View the Press Release
Announcement Icon

IVF at the SOTU: Fertility care expected to be major focus at State of the Union

Protecting access to IVF care is expected to be a major theme of the State of the Union on Thursday.

View the Press Release
Document Icon

Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion (2024)

Clinicians should encourage disclosure between intimate partners but should maintain confidentiality where there is no harm to the partner and/or offspring. View the Committee Opinion
Document Icon

Ethical considerations for telemedical delivery of fertility care: an Ethics Committee opinion (2024)

Telemedicine has the potential to increase access to and decrease the cost of care. View the Committee Opinion
Announcement Icon

ASRM Responds to Proposed Alabama Legislation

We are proud of our Alabama members and their patients, who have been such incredible advocates working to motivate their legislators to protect IVF.

View the Press Release
Announcement Icon

Senate Budget Hearing is Well Timed Following Alabama IVF Ruling

ASRM statement regarding the Senate Budget Committee’s hearing entitled: No Rights to Speak of: The Economic Harms of Restricting Reproductive Freedom.

View the Press Release
Announcement Icon

ASRM Responds to Senate’s Failure to Pass Access to Family Building Act

We are disappointed by the Senate’s failure to meet the moment and pass federal legislation protecting access to in vitro fertilization (IVF).

View the Press Release
News Icon

What's New from the Fertility and Sterility Family of Journals

Here’s a peek at this month’s issues from our family of journals! As an ASRM Member, you can access all of our journals.
Read More about the newest articles
Announcement Icon

ASRM Condemns Profoundly Misguided and Dangerous Court Decision in Alabama

In LePage v Mobile Infirmary Clinic, the Alabama Supreme Court made a decision that flies in the face of medical reality and the needs of the citizens.

View the Press Release
News Icon

NEW from ASRM Academy: Basic Infertility for Healthcare Providers

ASRM is proud to introduce our updated course: Basic Infertility for Healthcare Providers.  Learn more with an overview from Instructional Designer, Harriet Smith, MEd
News Icon

What's New from the Fertility and Sterility Family of Journals

Here’s a peek at this month’s issues from our family of journals! As an ASRM Member, you can access all of our journals. Not yet a member? Click here(no link) to learn more. Find More
Announcement Icon

ASRM applauds introduction of Access to Family Building Act of 2024

ASRM is thrilled by the introduction of the Access to Family Building Act 

View the Press Release
News Icon

Resource Roundup: Thyroid Health

January is Thyroid Health Awareness Month! View the resource roundup!
Document Icon

Definition of infertility: a committee opinion (2023)

‘‘Infertility’’ is a disease, condition, or status characterized by several factors. View the Committee Opinion
Podcast Icon

ASRM Today: ASRM Advocacy Training Initiative with Becca O'Connor

In this episode, ASRM Today talks with Becca O'Connor, of the ASRM Center for Policy and Leadership, about their first-of-its-kind advocacy training initiative. Listen to the Episode
Podcast Icon

ASRM Today: The Business of Infertility Treatment with Hary Hokianto

In this episode from ASRM 2023 in New Orleans, I'm talking with Hary Hokianto about the business of infertility treatment. Listen to the Episode
Document Icon

Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion (2023)

It is the responsibility of the clinician to assess for erectile dysfunction, ejaculatory dysfunction, or diminished libido in men presenting for infertility. View the Committee Opinion
Announcement Icon

Doctors Group Launches Ad Campaign for Ohio Issue 1

ASRM announced the launch of an ad campaign throughout Ohio urging voters to select “Yes on Issue 1” when they head to the polls on November 7.

View the Press Release
Videos Icon

Journal Club Global - Actualización en la suplementación con progesterona en fase lútea para transferencias de embriones congelados

Efectividad del rescate de progesterona en mujeres que presentan niveles bajos de progesterona circulante alrededor del día de la transferencia de embriones View the Video
Document Icon

Endometriosis and infertility: a committee opinion (2012)

Women with endometriosis typically present with pelvic pain, infertility, or an adnexal mass, and may require surgery. View the Committee Opinion
Document Icon

The International Glossary on Infertility and Fertility Care, 2017†‡§ (2017)

Terms and definitions currently used infertility care, infertility and medically assisted reproduction (MAR) can have different meanings that are dependent upon the setting, their usage in research or clinical interventions, or among diverse populations.
View the Committee Joint Guideline
Coding Icon

Post Vasectomy Infertility

If a husband has had a vasectomy, does the sterilization code apply to the wife's visits? View the Answer
Coding Icon

Pregnancy Of Uncertain Viability Ultrasound

My staff is telling me that I am getting reimbursed for the first sonogram and OB visit (using ICD 10 code for pregnancy of uncertain viability – O36.80X0. View the Answer
Coding Icon

Pregnancy Ultrasound

Our practice does routine ultrasounds (sac check- 76817) at the end of an IVF cycle and bill with a diagnosis code O09.081, pregnancy resulting from ART.  View the Answer
Coding Icon

Self-referred New Patient

A patient self-refers to our physician for an initial new patient consultation instead of referred by another physician, how do we code for the consult? View the Answer
Coding Icon

Telephone Consult

Does a physician need to speak directly to a patient to code for a telephone consult (99371-99373) or can a staff member relay physician notes to patients? View the Answer
Coding Icon

Testing With No History of Infertility

What diagnosis codes should  providers submit to insurance carriers while trying to evaluate fertility issues? View the Answer
Coding Icon

Psychological Evaluation

Many REs require patients (and their spouses/partners) who are considering using donor gametes to see an infertility counselor first. View the Answer
Coding Icon

Surgery Coding

I took the ASRM coding course, and in that course, coding for bilateral neosalpingostomies was coded using only a dx of N70.11 (hydrosalpinx). View the Answer
Coding Icon


Should other ovarian dysfunction (diagnosis code E28.8) or unspecified ovarian dysfunction (diagnosis code E28.9) can be used for an IUI or an IVF cycle View the Answer
Coding Icon

Infertility Consult

Does ASRM have any examples of evaluation and management documentation for patients being seen for an initial infertility evaluation? View the Answer
Coding Icon

Infertility Consult by Nurse

What code is used for a nurse practitioner seeing a fertility patient for the first time? View the Answer
Coding Icon

Initial Visit for Infertility With No Mandated Coverage

What code would be appropriate for an initial visit for infertility?  View the Answer
Coding Icon

Monitoring E&M

Our group would like to know if others are billing an evaluation and management code for ultrasound and blood draw visits? View the Answer
Coding Icon

New vs Established Patient

How soon can you bill as a new infertility patient? View the Answer
Coding Icon

General E&M Consult

Recently we have received a “re-code” on a new patient (we billed a 99203 and the insurance re-coded it to a 99213).  View the Answer
Coding Icon

Hysteroscopy Recurrent Implantation Failure

What is the appropriate ICD-10 code for recurrent implantation failure?  View the Answer
Coding Icon

Diagnosis of Infertility for IVF Procedure

How important is it to have accurate documentation of the type of infertility diagnosis for IVF procedures?  View the Answer
Coding Icon

Diagnostic Testing of an Infertile Couple

The Z31.41 is or is not the correct code to use for diagnostic testing of an infertile couple? And If so can if be used as the primary and only code? View the Answer
Coding Icon

D&C Under Ultrasound Guidance

What are the CPT codes and ICD-10 codes for coding a surgical case for a patient with history of Stage B adenocarcinoma of the cervix ... View the Answer
Coding Icon

Blood Draws

If a patient comes in only for a blood draw (venipuncture) and is seen only by the lab technician (not an MD, PA, or NP), may we bill for a (minimal) office visit? View the Answer
Coding Icon

Blood Tests

Patients are requesting to have lab work drawn from the female patient moved to the males account due to the female fertility coverage being maxed out.  View the Answer
Coding Icon

Male Infertility

A summary of common codes for Male Infertility compiled by the ASRM Coding Committee View the Coding Summary
Document Icon

ASRM müllerian anomalies classification 2021

The Task Force set goals for a new classification and chose to base it on the iconic AFS classification from 1988 because of its simplicity and recognizability. View the Committee Opinion
Document Icon

Intracytoplasmic sperm injection (ICSI) for non–male factor indications: a committee opinion (2020)

Intracytoplasmic sperm injection is frequently used in combination with assisted reproductive technologies. View the Committee Document
Document Icon

Moving innovation to practice: an Ethics Committee opinion (2021)

The introduction of new strategies, tests, and procedures into clinical practice raises challenging ethical issues. View the Committee Opinion
Document Icon

Fertility evaluation of infertile women: a committee opinion (2021)

Diagnostic evaluation for infertility in women should be conducted in a systematic, expeditious, and cost-effective manner. View the Committee Opinion
Document Icon

Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion (2020)

Pretreatment evaluation, indications, treatment regimens, and complications of gonadotropin treatment. View the Committee Opinion
Document Icon

Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review (2019)

Providers who care for women at risk for hereditary gynecologic cancers must consider the impact of these conditions. View the Joint Statement
Document Icon

Guidance for Providers Caring for Women and Men Of Reproductive Age with Possible Zika Virus Exposure (Updated 2019)

This ASRM guidance specifically addresses Zika virus infection issues and concerns of individuals undergoing assisted reproductive technologies (ART). View the Guideline
Document Icon

Current recommendations for vaccines for female infertility patients: a committee opinion (2018)

Encounters for infertility care are opportunities to assess and update immunization status. View the Committee Opinion
Document Icon

American Society for Reproductive Medicine position statement on uterus transplantation: a committee opinion (2018)

Following the birth of the first child from a transplanted uterus in Gothenburg, Sweden, in 2014, other centers worldwide have produced scientific reports. View the Committee Opinion
Document Icon

Child-rearing ability and the provision of fertility services: an Ethics Committee opinion (2017)

Fertility programs may withhold services from prospective patients on the basis of well-grounded reasons that those patients will be unable to provide minimally adequate or safe care for offspring. View the Committee Opinion
Document Icon

Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate: a guideline (2017)

This review evaluates if uterine myomas impact likelihood of pregnancy and pregnancy loss, and if myomectomy influences pregnancy outcomes. View the Guideline
Document Icon

Subclinical hypothyroidism in the infertile female population: a guideline (2015)

There is controversy regarding whether to treat subtle abnormalities of thyroid dysfunction in the infertile female patient. View the Committee Guideline
Document Icon

Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement (2014)

Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public. View the Guideline